Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1949 3
1950 1
1951 1
1952 1
1954 1
1955 3
1957 2
1958 3
1960 1
1964 2
1965 2
1966 1
1968 3
1969 8
1970 2
1972 2
1973 5
1974 8
1975 6
1976 4
1977 4
1978 4
1979 2
1980 3
1981 5
1982 7
1983 8
1984 8
1985 15
1986 19
1987 10
1988 20
1989 18
1990 18
1991 28
1992 37
1993 47
1994 44
1995 65
1996 55
1997 70
1998 59
1999 69
2000 59
2001 51
2002 67
2003 96
2004 72
2005 120
2006 122
2007 123
2008 121
2009 148
2010 202
2011 248
2012 245
2013 240
2014 252
2015 296
2016 253
2017 311
2018 327
2019 396
2020 458
2021 508
2022 673
2023 662
2024 176

Text availability

Article attribute

Article type

Publication date

Search Results

6,231 results

Results by year

Filters applied: . Clear all
Page 1
Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial.
Jin H, Zhang Y, Yu S, Du X, Xu N, Shao R, Lin D, Chen Y, Xiao J, Sun Z, Deng L, Liang X, Zhang H, Guo Z, Dai M, Shi P, Huang F, Fan Z, Yin Z, Xuan L, Lin R, Jiang X, Yu G, Liu Q. Jin H, et al. Among authors: lin r. J Hematol Oncol. 2023 Apr 29;16(1):42. doi: 10.1186/s13045-023-01437-1. J Hematol Oncol. 2023. PMID: 37120593 Free PMC article. Clinical Trial.
CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results.
Park JH, Nath K, Devlin SM, Sauter CS, Palomba ML, Shah G, Dahi P, Lin RJ, Scordo M, Perales MA, Shouval R, Tomas AA, Cathcart E, Mead E, Santomasso B, Holodny A, Brentjens RJ, Riviere I, Sadelain M. Park JH, et al. Among authors: lin rj. Nat Med. 2023 Jul;29(7):1710-1717. doi: 10.1038/s41591-023-02404-6. Epub 2023 Jul 3. Nat Med. 2023. PMID: 37400640 Clinical Trial.
Anthracyclines inhibit SARS-CoV-2 infection.
Wang Z, Pan Q, Ma L, Zhao J, McIntosh F, Liu Z, Ding S, Lin R, Cen S, Finzi A, Liang C. Wang Z, et al. Among authors: lin r. Virus Res. 2023 Sep;334:199164. doi: 10.1016/j.virusres.2023.199164. Epub 2023 Jun 28. Virus Res. 2023. PMID: 37379907 Free PMC article.
Metal-organic framework glass composites.
Lin R, Chai M, Zhou Y, Chen V, Bennett TD, Hou J. Lin R, et al. Chem Soc Rev. 2023 Jul 3;52(13):4149-4172. doi: 10.1039/d2cs00315e. Chem Soc Rev. 2023. PMID: 37335141 Review.
SF3B1 mutation and ATM deletion codrive leukemogenesis via centromeric R-loop dysregulation.
Cusan M, Shen H, Zhang B, Liao A, Yang L, Jin M, Fernandez M, Iyer P, Wu Y, Hart K, Gutierrez C, Nik S, Pruett-Miller SM, Stark J, Obeng EA, Bowman TV, Wu CJ, Lin RJ, Wang L. Cusan M, et al. Among authors: lin rj. J Clin Invest. 2023 Sep 1;133(17):e163325. doi: 10.1172/JCI163325. J Clin Invest. 2023. PMID: 37463047 Free PMC article.
6,231 results